RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults

V. Cárdenas (Spring House, PA, United States of America), M. Le Gars (Leiden, Netherlands), J. Sadoff (Leiden, Netherlands), J. Ruiz Guiñazú (Beerse, Belgium), N. Vaissière (Beerse, Belgium), C. Truyers (Beerse, Belgium), G. Scheper (Leiden, Netherlands), F. Struyf (Beerse, Belgium), J. Hendriks (Leiden, Netherlands), H. Schuitemaker (Leiden, Netherlands), M. Douoguih (Leiden, Netherlands)

Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term
Session: Challenges of COVID-19 management at short and long-term
Session type: E-poster
Number: 489

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Cárdenas (Spring House, PA, United States of America), M. Le Gars (Leiden, Netherlands), J. Sadoff (Leiden, Netherlands), J. Ruiz Guiñazú (Beerse, Belgium), N. Vaissière (Beerse, Belgium), C. Truyers (Beerse, Belgium), G. Scheper (Leiden, Netherlands), F. Struyf (Beerse, Belgium), J. Hendriks (Leiden, Netherlands), H. Schuitemaker (Leiden, Netherlands), M. Douoguih (Leiden, Netherlands). RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults. 489

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial
Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019
Year: 2019



Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial
Source: Eur Respir J 2002; 20: Suppl. 38, 146s
Year: 2002

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
Source: Eur Respir J 2016; 48: 320-330
Year: 2016



The safety and immunogenicity of a conjugated nicotine vaccine: results from a double-blind, placebo-controlled trial in healthy smokers and non-smokers
Source: Annual Congress 2004 - Update on smoking related damage and cessation
Year: 2004


“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial)
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013


INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020


Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial
Source: Annual Congress 2008 - Physiological response to exercise performance
Year: 2008


Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming
Source: Eur Respir J 2003; 22: Suppl. 45, 388s
Year: 2003

A multicenter randomized phase III-trial with carboplatin (C) and paclitaxel (P) in advanced NSCLC: preliminary results of dose adjusted weekly schedule, compared to standard regime (q3w)
Source: Annual Congress 2004 - Management of lung cancer and innovative therapies
Year: 2004


Effects of exercise training after lung transplantation: 1 year follow-up of a randomized controlled trial
Source: Annual Congress 2011 - Exercise training: new populations, new techniques
Year: 2011


Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



A randomized, open-label, parallel design study to compare the immunogenicity of simultaneous administration versus sequential administration of quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis  
Year: 2017


Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking
Source: Eur Respir J 2002; 20: Suppl. 38, 611s
Year: 2002

Efficacy of esomeprazole 40 mg twice daily for 16 weeks in adults with asthma: a randomised placebo-controlled trial
Source: Eur Respir J 2005; 26: Suppl. 49, 278s
Year: 2005

Safety and immunogenicity of a dose-sparing, trivalent inactivated seasonal influenza vaccine containing an advax adjuvant – a phase 1/2 randomised controlled trial
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Year: 2008


Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020
Year: 2020



Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021